TTC12

Across TCGA pan-cancer cohorts, TTC12 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TTC12 data layer compared with 20 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TTC12 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TTC12 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, CCRCC, and LUAD are the cancer types where TTC12 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.890	0.580	.001	53	view →
CCRCC	OS	Median	III,IV	0.133	0.985	.027	13	view →
LUAD	OS	Median	III,IV	0.757	0.349	.046	2	view →
LSCC	DFS	Tertile	II,III,IV	0.831	1.000	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TTC12–HNSC (OS)

Open the HNSC breakdown →